Outcomes following Thulium vapoenucleation of large prostates

Shane M. Pearce, Joseph J. Pariser, Rena D. Malik, Olufenwa J. Famakinwa, Doreen E. Chung

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Thulium laser VapoEnucleation of the prostate (ThuVEP) is an evolving surgical technique for BPH. Most studies have focused on outcomes in small to medium sized prostates and have originated from Europe and Asia. We sought to describe our experience with ThuVEP for very large prostates in a North American cohort. Materials and Methods: From December 2010 to October 2014, 25 men underwent Thu- VEP using the CyberTM® (Quantastem, Italy) thulium laser, all with prostate volume > 75mL. Data collected included patient demographics, comorbidities, intraoperative parameters, complications, and post-operative outcomes including maximum flow rate (Qmax), post-void residual (PVR), International Prostate Symptom Score (IPSS), and quality of life score (QoL) in one year of follow-up. Statistical analysis was done using Wilcoxon signed-rank test. Results: At baseline, mean age was 70±9 years and prostate size was 163±62g. Most patients (84%) were in retention and 10 (40%) patients were on anticoagulation. Seven (28%) patients went home the day of surgery (mean hospital stay: 1.2±1.2d). There were 2 intraoperative complications (8%), both cystotomies related to morcellation. Nine patients (36%) experienced a complication, all within 30 days. There were no Clavien ≥ III complications. Significant improvements were seen in Qmax, PVR, IPSS, and QoL score at each time interval to 12-months following surgery (all p < 0.05). Of 21 patients initially in retention, all were voiding at last follow-up. Conclusions: Our findings suggest that ThuVEP is an effective treatment for BPH in patients with large prostates with sustained results for one year.

Original languageEnglish (US)
Pages (from-to)757-765
Number of pages9
JournalInternational Braz J Urol
Volume42
Issue number4
DOIs
StatePublished - Jan 1 2016

Fingerprint

Thulium
Prostate
Lasers
Intraoperative Complications
Cystotomy
Quality of Life
Nonparametric Statistics
Ambulatory Surgical Procedures
Italy
Comorbidity
Length of Stay

Keywords

  • Prostatic hyperplasia
  • Quality of life
  • Thulium
  • Treatment outcome
  • Urinary tract

Cite this

Outcomes following Thulium vapoenucleation of large prostates. / Pearce, Shane M.; Pariser, Joseph J.; Malik, Rena D.; Famakinwa, Olufenwa J.; Chung, Doreen E.

In: International Braz J Urol, Vol. 42, No. 4, 01.01.2016, p. 757-765.

Research output: Contribution to journalArticle

Pearce, Shane M. ; Pariser, Joseph J. ; Malik, Rena D. ; Famakinwa, Olufenwa J. ; Chung, Doreen E. / Outcomes following Thulium vapoenucleation of large prostates. In: International Braz J Urol. 2016 ; Vol. 42, No. 4. pp. 757-765.
@article{83ce8e3c27d249a7aa31784436311924,
title = "Outcomes following Thulium vapoenucleation of large prostates",
abstract = "Introduction: Thulium laser VapoEnucleation of the prostate (ThuVEP) is an evolving surgical technique for BPH. Most studies have focused on outcomes in small to medium sized prostates and have originated from Europe and Asia. We sought to describe our experience with ThuVEP for very large prostates in a North American cohort. Materials and Methods: From December 2010 to October 2014, 25 men underwent Thu- VEP using the CyberTM{\circledR} (Quantastem, Italy) thulium laser, all with prostate volume > 75mL. Data collected included patient demographics, comorbidities, intraoperative parameters, complications, and post-operative outcomes including maximum flow rate (Qmax), post-void residual (PVR), International Prostate Symptom Score (IPSS), and quality of life score (QoL) in one year of follow-up. Statistical analysis was done using Wilcoxon signed-rank test. Results: At baseline, mean age was 70±9 years and prostate size was 163±62g. Most patients (84{\%}) were in retention and 10 (40{\%}) patients were on anticoagulation. Seven (28{\%}) patients went home the day of surgery (mean hospital stay: 1.2±1.2d). There were 2 intraoperative complications (8{\%}), both cystotomies related to morcellation. Nine patients (36{\%}) experienced a complication, all within 30 days. There were no Clavien ≥ III complications. Significant improvements were seen in Qmax, PVR, IPSS, and QoL score at each time interval to 12-months following surgery (all p < 0.05). Of 21 patients initially in retention, all were voiding at last follow-up. Conclusions: Our findings suggest that ThuVEP is an effective treatment for BPH in patients with large prostates with sustained results for one year.",
keywords = "Prostatic hyperplasia, Quality of life, Thulium, Treatment outcome, Urinary tract",
author = "Pearce, {Shane M.} and Pariser, {Joseph J.} and Malik, {Rena D.} and Famakinwa, {Olufenwa J.} and Chung, {Doreen E.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1590/S1677-5538.IBJU.2015.0424",
language = "English (US)",
volume = "42",
pages = "757--765",
journal = "International braz j urol : official journal of the Brazilian Society of Urology",
issn = "1677-5538",
publisher = "Brazilian Society of Urology",
number = "4",

}

TY - JOUR

T1 - Outcomes following Thulium vapoenucleation of large prostates

AU - Pearce, Shane M.

AU - Pariser, Joseph J.

AU - Malik, Rena D.

AU - Famakinwa, Olufenwa J.

AU - Chung, Doreen E.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Introduction: Thulium laser VapoEnucleation of the prostate (ThuVEP) is an evolving surgical technique for BPH. Most studies have focused on outcomes in small to medium sized prostates and have originated from Europe and Asia. We sought to describe our experience with ThuVEP for very large prostates in a North American cohort. Materials and Methods: From December 2010 to October 2014, 25 men underwent Thu- VEP using the CyberTM® (Quantastem, Italy) thulium laser, all with prostate volume > 75mL. Data collected included patient demographics, comorbidities, intraoperative parameters, complications, and post-operative outcomes including maximum flow rate (Qmax), post-void residual (PVR), International Prostate Symptom Score (IPSS), and quality of life score (QoL) in one year of follow-up. Statistical analysis was done using Wilcoxon signed-rank test. Results: At baseline, mean age was 70±9 years and prostate size was 163±62g. Most patients (84%) were in retention and 10 (40%) patients were on anticoagulation. Seven (28%) patients went home the day of surgery (mean hospital stay: 1.2±1.2d). There were 2 intraoperative complications (8%), both cystotomies related to morcellation. Nine patients (36%) experienced a complication, all within 30 days. There were no Clavien ≥ III complications. Significant improvements were seen in Qmax, PVR, IPSS, and QoL score at each time interval to 12-months following surgery (all p < 0.05). Of 21 patients initially in retention, all were voiding at last follow-up. Conclusions: Our findings suggest that ThuVEP is an effective treatment for BPH in patients with large prostates with sustained results for one year.

AB - Introduction: Thulium laser VapoEnucleation of the prostate (ThuVEP) is an evolving surgical technique for BPH. Most studies have focused on outcomes in small to medium sized prostates and have originated from Europe and Asia. We sought to describe our experience with ThuVEP for very large prostates in a North American cohort. Materials and Methods: From December 2010 to October 2014, 25 men underwent Thu- VEP using the CyberTM® (Quantastem, Italy) thulium laser, all with prostate volume > 75mL. Data collected included patient demographics, comorbidities, intraoperative parameters, complications, and post-operative outcomes including maximum flow rate (Qmax), post-void residual (PVR), International Prostate Symptom Score (IPSS), and quality of life score (QoL) in one year of follow-up. Statistical analysis was done using Wilcoxon signed-rank test. Results: At baseline, mean age was 70±9 years and prostate size was 163±62g. Most patients (84%) were in retention and 10 (40%) patients were on anticoagulation. Seven (28%) patients went home the day of surgery (mean hospital stay: 1.2±1.2d). There were 2 intraoperative complications (8%), both cystotomies related to morcellation. Nine patients (36%) experienced a complication, all within 30 days. There were no Clavien ≥ III complications. Significant improvements were seen in Qmax, PVR, IPSS, and QoL score at each time interval to 12-months following surgery (all p < 0.05). Of 21 patients initially in retention, all were voiding at last follow-up. Conclusions: Our findings suggest that ThuVEP is an effective treatment for BPH in patients with large prostates with sustained results for one year.

KW - Prostatic hyperplasia

KW - Quality of life

KW - Thulium

KW - Treatment outcome

KW - Urinary tract

UR - http://www.scopus.com/inward/record.url?scp=84991094798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991094798&partnerID=8YFLogxK

U2 - 10.1590/S1677-5538.IBJU.2015.0424

DO - 10.1590/S1677-5538.IBJU.2015.0424

M3 - Article

C2 - 27564287

AN - SCOPUS:84991094798

VL - 42

SP - 757

EP - 765

JO - International braz j urol : official journal of the Brazilian Society of Urology

JF - International braz j urol : official journal of the Brazilian Society of Urology

SN - 1677-5538

IS - 4

ER -